Search

Displaying results 2801 - 2810 of 4590 in total
  1. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  2. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    It was researched in the 1960s and 1970s but never marketed.

  3. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    It was previously marketed in France as Lutionex, but has since been discontinued.

  4. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.

  5. Drug

    Dienestrol

    go.drugbank.com/drugs/DB00890
    ApprovedWithdrawn

    Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy.

  6. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).

  7. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.

  8. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary.

  9. Drug

    Verpasep caltespen

    go.drugbank.com/drugs/DB04959
    Investigational

    It is being developed by StressGen Biotechnologies Corp. … E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes.

  10. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular degeneration.